Motoneurone Disease Stroke Peripheral Neuropathy Multiple Sclerosis
Drug Platform Publications Collaborations
Our Mission Management Team Advisory Boards


CuroNZ News

CuroNZ is pleased to report high level pre-clinical results achieved in patient dog studies in collaboration with Dr Roger Clemmons, Associate professor of Neurology for animals at the University of Florida.  He has applied intra-muscular NRP injections to several patient dogs suffering from spinal cord injury, eye diseases and the dog equivalent of progressive Multiple Sclerosis (degenerative myelopathy). 

We have uploaded a video of ‘Buc’ the dog who has spinal cord injury and the dog equivalent of retinitis pigmentosa, the video shows before and after NRP walking, gait and movement.  Click to view Video. 

Since having NRP injections Buc's eyesight has not deteriorated as would normally be expected in this timeframe and as you can see on the video his gait and walking is much improved.

CuroNZ is a small biotechnology company with a patent portfolio and platform of drugs relevant for the pharmaceutical industry.

Our Managing Director, Dr Frank Sieg discovered  a gene family of encoding proteins with highly bioactive and drugable short stretches of amino acids.  

Dr Sieg was formerly the Principal Scientist/Team Leader of Gene Discovery and Invitro Systems at Neuren Pharmaceuticals Ltd, and before that Neuronz Pharmaceuticals Ltd, where the drug development program took place over a period of 7 years.

The lead compound’s unique properties include:neuro regenerative properties

  • initiation of neuronal proliferation and migration (also called neurogenesis)
  • promotion of cellular differentiation (including outgrowth of electrically active nerve fibres)
  • cellular survival-enhancing pharmacodynamic activity

With $3.5million spent to date on these compound’s development by Neuren Pharmaceuticals they are now in the mid to late stage of preclinical development. 

We are initially looking for partners and investors to work with to develop the drug to the end of preclinical development  and in return we aim to offer a high rate of return.

With our highly experienced neuroscientists, advisors and the other team members we intend to develop our drugs with the highest possible benefit to cost ratio. 

Our ultimate aim is to contribute to the development of effective treatments for some of the most seriously debilitating central nervous system diseases and conditions.